CELLECTIS S.A.

In News

Cellectis (NASDAQ: CLLS) widens 2025 loss while CAR-T pipeline advances - Stock Titan

Stock Titan - Mar 19, 2026

Cellectis Bets on Non-Viral Editing for Therapy Gains - crisprmedicinenews.com

crisprmedicinenews.com - Jan 28, 2026

Cellectis SA reports results for the quarter ended December 31 - Earnings Summary - TradingView

TradingView - Mar 20, 2026

Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising - GuruFocus

GuruFocus - Mar 20, 2026

AstraZeneca, Cellectis targeted in patent lawsuit over gene-editing technology - Reuters

Reuters - Sep 26, 2025

Cellectis S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

marketscreener.com - Mar 20, 2026

Cellectis S.A. Sets March 19 Release Date for Q4 and Full-Year 2025 Results - TipRanks

TipRanks - Mar 12, 2026

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS) - Seeking Alpha

Seeking Alpha - Dec 18, 2025

Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents - PR Newswire

PR Newswire - Sep 26, 2025

AstraZeneca, Cellectis Sued Over $2.2 Billion Cancer-Drug Deal - Bloomberg Law News

Bloomberg Law News - Sep 26, 2025

Cellectis (NASDAQ: CLLS) schedules Q4 and full-year 2025 earnings call - Stock Titan

Stock Titan - Mar 12, 2026

Cellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS) - Seeking Alpha

Seeking Alpha - Dec 11, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment